GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (OTCPK:ASCLF) » Definitions » Short-Term Debt

ASCLF (Ascletis Pharma) Short-Term Debt : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascletis Pharma Short-Term Debt?

Ascletis Pharma's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.


Ascletis Pharma Short-Term Debt Historical Data

The historical data trend for Ascletis Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Short-Term Debt Chart

Ascletis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only - - - - -

Ascletis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ascletis Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Ascletis Pharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.

Ascletis Pharma Headlines